Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 7/20 | 0.60 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.56 |
| ▸ | ALB | P02768 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12087585 | 1.00 | TK1 (0.60) | TK1RNASE1ALBPKMLMNA | |
| SCHEMBL26189529 | 1.00 | TK1 (0.60) | TK1RNASE1ALBPKMLMNA | |
| SCHEMBL15236309 | 0.89 | TK1 (0.59) | TK1RNASE1ALBPKMLMNA | |
| SCHEMBL12360859 | 0.89 | TK1 (0.59) | TK1RNASE1ALBPKMLMNA | |
| SCHEMBL523267 | 0.89 | RNASE1 (0.69) | TK1RNASE1ALBPKMLMNA | |
| SCHEMBL23102036 | 0.89 | TK1 (0.56) | TK1RNASE1ALBPKMLMNA | |
| SCHEMBL12670320 | 0.89 | RNASE1 (0.69) | TK1RNASE1ALBPKMLMNA | |
| SCHEMBL10431982 | 0.89 | RNASE1 (0.69) | TK1RNASE1ALBPKMLMNA | |
| SCHEMBL16426201 | 0.89 | TK1 (0.59) | TK1RNASE1ALBPKMLMNA | |
| SCHEMBL25756080 | 0.89 | RNASE1 (0.69) | TK1RNASE1ALBPKMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9803199-B2 | Cationic lipid | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-10-31 | — | — | US | disclosed |
| US-20160257951-A1 | NOVEL LIPID | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-09-08 | — | — | US | disclosed |
| US-8987226-B2 | Modified single-stranded polynucleotides | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-03-24 | — | — | US | disclosed |
| US-20120220649-A1 | MODIFIED DOUBLE-STRANDED POLYNUCLEOTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20070117773-A1 | Telomerase-inhibiting ENA oligonucleotide | SANKYO COMPANY, LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| EP-1783216-A1 | TELOMERASE-INHIBITORY ENA OLIGONUCLEOTIDE | Sankyo Company, Limited (JP) | 2007-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257951-A1 | NOVEL LIPID | NPC1L1, CETP, LIPC | TK1 3293/4885RNASE1 349/4885ALB 3509/4885 |
| US-20120220649-A1 | MODIFIED DOUBLE-STRANDED POLYNUCLEOTIDE | POLM, POLN, PNKP | TK1 86/4885RNASE1 208/4885ALB 4626/4885 |
| US-20070117773-A1 | Telomerase-inhibiting ENA oligonucleotide | TERT, ENO1, TERB1 | TK1 192/4885RNASE1 88/4885ALB 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.